LEADER 04952nam 2201273z- 450 001 9910557627203321 005 20231214132946.0 035 $a(CKB)5400000000045143 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69332 035 $a(EXLCZ)995400000000045143 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTuberculosis Drug Discovery and Development 2019 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (296 p.) 311 $a3-03943-236-2 311 $a3-03943-237-0 330 $aTuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue. 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $amycobacteria 610 $atuberculosis 610 $amulti-drug resistance 610 $adrug discovery 610 $apromiscuous targets 610 $aMycobacterium tuberculosis 610 $arifampin 610 $aisoniazid 610 $amechanisms of resistance 610 $amutations 610 $agranulomas 610 $acaseum 610 $acell envelope 610 $adormancy 610 $adelpazolid 610 $amacozinone 610 $aDprE1 inhibitor 610 $aclinical studies 610 $adiscovery 610 $amode of action 610 $adrug resistance 610 $atoxicity 610 $atarget 610 $aenergy metabolism 610 $aelectron transport chain 610 $aoxidative phosphorylation 610 $abedaquiline 610 $aQ203 610 $aMID3 610 $apharmacokinetics 610 $apharmacodynamics 610 $adrug-drug interactions 610 $ain vitro 610 $ain vivo 610 $adrug development 610 $atuberculosis treatment 610 $abiomarkers 610 $adrug combination 610 $aclinical trial 610 $aBCG 610 $atuberculosis vaccines 610 $aTBVI 610 $aEDCTP 610 $aIAVI 610 $aCTVD 610 $ahost-directed therapy 610 $aanti-virulence compounds 610 $aTB 610 $apost-treatment sequelae 610 $asurgery 610 $apulmonary rehabilitation 610 $aCarlo Forlanini 610 $aartificial pneumothorax 610 $astructure-based drug design 610 $atarget-based drug design 610 $aPknB 610 $aPknG 610 $aDNA gyrase 610 $aantibiotic 610 $amycobacterium 610 $agenomics 610 $atranscriptomics 610 $aproteomics 610 $ametabolomics 610 $alipidomics 610 $atarget identification 610 $amechanism of action 610 $aantimicrobial drug resistance (AMR) 610 $atarget-based screening 610 $aphenotypic screening 610 $aantituberculosis agents 610 $aantimycobacterial 610 $aanti-TB drug pipeline 610 $aprivileged targets 610 $alead generation 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aRiccardi$b Giovanna$4edt$0535511 702 $aSala$b Claudia$4edt 702 $aRiccardi$b Giovanna$4oth 702 $aSala$b Claudia$4oth 906 $aBOOK 912 $a9910557627203321 996 $aTuberculosis Drug Discovery and Development 2019$93026529 997 $aUNINA